Close
果冻影院鈥檚 first Advanced Therapies Symposium: Unveiling one of the largest pipelines from lab to market
25 April 2024
果冻影院 scientists gathered at the symposium to discuss their research in advanced therapies, from laboratories into commercialisation. The extensive pipelines unveil a huge potential for collaborations with research and commercial partners to bring life-changing impact to patients.
Photo 1: Professor Geraint Rees, Vice-Provost (Research, Innovation & Global Engagement) at 果冻影院, spoke at the 果冻影院 Advanced Therapies Symposium to highlight the unique ecosystem and partnerships built for 果冻影院's ATMP success.
On 24 April, 果冻影院 launched its first Advanced Therapies Symposium that attracted over 250 attendees from 果冻影院 and beyond, including 果冻影院 scientists, research and clinical collaborators, funding entities, and healthcare industry leaders specialising in Advanced Therapy Medicinal Product (ATMP) research and developments.
The ATMP report, released during the symposium, lays out the 果冻影院鈥檚 key statistics in its ATMP research and commercialisation projects which represents one of the world鈥檚 largest development pipelines for Advanced Therapy Medicinal Products (ATMP). It demonstrates the extensive experimental and clinical expertise spanning across disciplines, highlighting specialisms in Rare Diseases, Ophthalmology, Haematology/Oncology, Neurology, and Immunology.
Key figures from the report include:
- 100+ projects in development, from discovery, clinical trials through to market launch.
- Close to 拢80M in public funding to support the current active projects spanning preclinical stage and Phase I/II trials.
- One treatment for haemophilia A, 搁辞肠迟补惫颈补苍鈩�, already licenced in the U.S and EU through 果冻影院鈥檚 partner Biomarin.
- 54% of the UK鈥檚 entire ATMP academically sponsored clinical trials are conducted via 果冻影院 partner hospitals.
- 43% of the UK鈥檚 commercial sponsored trials are delivered by 果冻影院 partner hospitals.
The figures underline not just the research excellence of these complex therapies at 果冻影院, but also its leading position in moving the advanced therapy field out of the research laboratories into commercialisation, with approved drugs being delivered to patients.
Over the past 10 years, 果冻影院 has successfully spun out twelve advanced therapy companies, which collectively have received in excess of 拢2Bn of external investment, with five companies having IPO鈥檇.
At the symposium, 果冻影院 scientists discussed their expertise in advanced therapies, with a focus on 果冻影院's early-stage research and clinical experience, alongside presentations on successful case studies. Panel discussions on industry and venture capital (VC) investments in spinouts, as well as clinical experience in delivering these complex therapies, inspired immense knowledge exchange on and off the stage.
Chairing the panel discussion on industry and VC investments, Dr. Anne Lane, CEO of 果冻影院 Business (果冻影院B), said, "The coordinated support between 果冻影院, 果冻影院B, and its partner hospitals鈥攆rom science-trained business managers, translational research experts, and clinical facilities and units鈥攃reates a unique position for 果冻影院 to make every step towards successful commercialisation, helping to de-risk projects and maximise venture capital investment."听
Professor Geraint Rees, Vice-Provost (Research, Innovation & Global Engagement) at 果冻影院, added in his closing remarks, "It is the precious ecosystem we have created over the years and partnerships with various stakeholders 鈥� from patients, hospitals, funding, research, and investment partners 鈥� that make 果冻影院 a global leader in advanced therapies. Our R&D and clinical pipelines are supported by unparalleled commercial pipelines along the translational pathway, enabling us to make a real impact on individual lives."听
The symposium is organised by the 果冻影院 Translational Research Office (TRO) and the Therapeutic Innovation Networks (TINs), and chaired by Professor Simon Waddington, Professor of Gene Therapy and Maternal & Fetal Medicine at 果冻影院, who leads the Cell and Gene Therapy network under the TINs.
Photo 2: Professor Simon Waddington, Professor of Gene Therapy and Maternal & Fetal Medicine at 果冻影院, kicked off 果冻影院鈥檚 first Advanced Therapies Symposium.
Photo 3:听Dr. Anne Lane, CEO of 果冻影院 Business, led the panel discussion on industry and venture capital investments in spinouts, joined by Professor Emma Morris (果冻影院), Professor Bobby Gaspar (果冻影院), Dr. Richard Fagan (果冻影院B), and Dr. Elisa Petris (Syncona Investment Management Ltd).
Photo 4:听Professor Dimitri Michael Kullmann, Professor of Clinical and Experimental Epilepsy at 果冻影院 Queen Square Institute of Neurology, led the panel discussion on 果冻影院鈥檚 clinicians' experience, joined by Professors Amit Nathwani, Sarah Tabrizi, Manju Kurian, and Claire Booth.
Photo 5a-b:听果冻影院 early career researchers (ECRs) across research disciplines showcased their research posters at the event and exchanged ideas with the attendees.
Photo 6a-b:听The 果冻影院 Advanced Therapies Symposium presented unprecedented networking opportunities between 果冻影院 scientists and its research and industry partners, generating leads for potential collaboration opportunities.
Photo 7a-b:听果冻影院鈥檚 first Advanced Therapies Symposium attracted over 250 attendees from 果冻影院 and beyond, including 果冻影院 scientists, research and clinical collaborators, funding entities, and healthcare industry leaders specialising in Advanced Therapy Medicinal Product (ATMP) research and developments.听
听
Read more:
- 果冻影院 ATMP report
- 果冻影院 Translational Research Office (TRO)
- 果冻影院 Therapeutic Innovation Networks (TINs)
(果冻影院B) - US regulator approves first ever gene therapy for people with haemophilia A
- New gene therapy could significantly reduce seizures in severe childhood epilepsy
- 果冻影院 spin out Quell Therapeutics joins forces with AstraZeneca in $2billion deal
- 果冻影院 spinout pioneers rare disease gene therapy to treat children with severe genetic disorders
Session chairs and panellists:
External panellist:
Sponsors:
Interested to stay informed of upcoming news, events and funding calls?
Subscribe to our newsletter听and you would automatically become a member of 果冻影院 TINs (Therapeutic Innovation Networks) and be the first to receive our event invitations
Follow听us on social media (,听)听and stay tuned to our news and updates.